MeiraGTx reports preclinical gene therapy data showing retinal protection in dry AMD models
MGTX•MGTX•MGTX•MGTX•MeiraGTx said AAV-NRF2 protected retinal cells from oxidative damage in preclinical dry AMD models. The company will present four research posters at the ESGCT congress and NEALS annual meeting, scheduled for October 27-30, 2026.
MeiraGTx will present four research posters at the ESGCT congress and NEALS annual meeting, both scheduled for October 27-30, 2026. Results for AAV-NRF2, which protected retinal cells from oxidative damage in preclinical dry AMD models, are scheduled for presentation October 29.
Optimized AAV-hUPF1 improved neuronal function in patient-derived cells and motor neuron survival in an ALS mouse model. The findings, scheduled for presentation October 28, also include early expression studies supporting development of AAV-hCNTFRα.
Additional ESGCT posters cover analytical methods intended to support gene therapy product characterization, quality control and future commercial licensing.
